A Phase 2/3 interventional study of Ataciguat and Placebo in Moderate Aortic Valve Stenosis, sponsored by Kardigan, Inc.. Recruiting at 74 sites in 2 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Kardigan, Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 189 studies in Aortic Valve Stenosis with a site in United States — 44 open to participants now, 68 under way, 3 of them phase 3. Aortic Valve Stenosis · United States.
Among the 189 studies in Aortic Valve Stenosis with a site in United States, this one is the 15th largest by planned enrollment of the 125 interventional ones that give a count, is one of 12 that started in 2025, is one of 2 in phase 2/3, reaches primary completion later than 51 of the 67 other live ones, and was the 175th registered.
1,026 studies on the registry are indexed under Aortic Valve Stenosis; 294 are open to participants now.
Browse Aortic Valve Stenosis studies →44 of the 189 studies in Aortic Valve Stenosis with a site in United States are open now. Recruiting first, the newest first:
American College of Cardiology · Sites in United States
Ages 18+
EmStop Inc · Sites in United States
Ages 22+
Dermed Diagnostics, Inc. · Sites in United States
Ages 18+
Columbia University · Sites in United States
Ages 18+
MiRus · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 25 take children under 18; 14 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
189 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 7 · Phase 3 7 · Phase 4 6
First in 2000; this study’s year is marked. 12 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,276 is above the median of 126 across 554 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 172 across the 125 interventional studies, 102 across the 64 observational. Of the 106 that completed or were terminated, 50 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 189 have an industry lead sponsor. The 10 most frequent:
Kardigan, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Kardigan, Inc. has 1 study filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
13 of the studies in Aortic Valve Stenosis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06689839EnCompass Technologies, Inc.Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR | 2026-12 |
| NCT05603026University Hospitals Cleveland Medical CenterMRI in Transcatheter Aortic Valve Replacement Patients | 2026-12-30 |
| NCT07827105AccurKardia, Inc.ECG-based AI Screening for Cases of Undiagnosed Moderate-to-Severe Aortic Stenosis in the Primary Care Setting | 2027-02 |
| NCT06077201Vanderbilt University Medical CenterHome-Based Cardiac Rehabilitation Using a Novel Mobile Health Exercise Regimen Following Transcatheter Heart Valve Interventions | 2027-02-01 |
| NCT06580158Mayo ClinicAI in Outpatient Practice for Diagnosing Aortic Stenosis and Diastolic Dysfunction | 2027-03 |
Add all 13 to your calendar (.ics) → With an account.
Among the 189 studies in Aortic Valve Stenosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate if ataciguat slows the progression of moderate calcific aortic valve stenosis in adults.
This study will be conducted in two parts: Part A and Part B. The purpose of Part A is to investigate whether ataciguat slows the progression of aortic valve calcium (AVC) deposition in adults with moderate calcific aortic valve stenosis (CAVS). The safety, tolerability, and pharmacokinetics of ataciguat will also be evaluated. Approximately 132 participants will be enrolled in Part A. Enrollment in Part B will begin once enrollment in Part A is complete. The purpose of Part B is to investigate whether ataciguat slows the rate of aortic valve area (AVA) loss and to evaluate the effect of ataciguat on peak oxygen consumption (VO2) in participants with moderate CAVS. The safety and tolerability of ataciguat will also be evaluated. Approximately 1144 participants will be enrolled in Part B.
Key Inclusion Criteria:
Has moderate CAVS as defined by:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ataciguat
Drug: Placebo
Ataciguat will be administrated daily for up to 156 weeks
Placebo will be administrated daily for up to 156 weeks
(Part A) Change in Aortic Valve Calcium (AVC) score as assessed by non-contrast CT from baseline to Week 24
Time frame: Week 24
(Part B Dual-Primary) Percent change in Aortic Valve Area (AVA) as measured by echocardiogram from baseline to Week 48
Time frame: Week 48
(Part B Dual-Primary) Change in peak VO2 by CPET from baseline to Week 48
Time frame: Week 48
(Part A) Correlation in the change in AVC as assessed by non-contrast CT and change in VO2 at Week 48
Time frame: Week 48
(Part A) Change in VO2 from baseline to Week 48
Time frame: Week 48
Change in left ventricular diastolic function as assessed by E/e' from baseline to Week 48
Time frame: Week 48
(Part A) Change in Left Ventricular Mass Index (LVMI) from baseline to Week 48
Time frame: Week 48
(Part A) Change in Kansas City Cardiomyopathy Questionnaire-23 (KCCQ-23) from baseline to Week 48
KCCQ-23 is a patient reported outcome instrument with minimum score = 0 and maximum score = 100 where higher score indicates better health status. There are no units to the score.
Time frame: Week 48
(Part B) Change in AVC score as assessed by non-contrast CT from baseline to Week 48
Time frame: Week 48
(Part B) Time to decision to proceed with TAVR/SAVR or all-cause death
Time frame: Week 158
(Part B) Percentage of participants with progression to AVA <1.0cm2 at Week 48
Time frame: Week 48
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for Aug 2028, 38 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ataciguat
Kardigan, Inc.